- Home
- CLSD
as 12-18-2024 10:34am EST
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | ALPHARETTA |
| Market Cap: | 76.6M | IPO Year: | 2016 |
| Target Price: | $5.33 | AVG Volume (30 days): | 230.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.92 - $2.12 | Next Earning Date: | 11-12-2024 |
| Revenue: | $7,703,000 | Revenue Growth: | 248.39% |
| Revenue Growth (this year): | -80.71% | Revenue Growth (next year): | 91.87% |
Stock Insider Trading Activity of Clearside Biomedical Inc. (CLSD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chong Ngai Hang Victor | CLSD | Chief Medical Officer | Nov 1 '24 | Buy | $1.00 | 36,500 | $36,500.00 | 100,000 |
Latest Clearside Biomedical Inc. News
CLSD Breaking Stock News: Dive into CLSD Ticker-Specific Updates for Smart Investing
Zacks
6 days ago
Here's Why Clearside Biomedical (CLSD) Is a Great 'Buy the Bottom' Stock Now
GlobeNewswire
23 days ago
Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States
Zacks
a month ago
All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy
Simply Wall St.
a month ago
Clearside Biomedical Third Quarter 2024 Earnings: Beats Expectations
GuruFocus.com
a month ago
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights: Promising Clinical Trial ...
Zacks
a month ago
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
a month ago
Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
GuruFocus.com
a month ago
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Report Preview: What to Look For
Compare CLSD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLSD Clearside Biomedical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.